

Appl. N. 09/934,773
Amdt. dated April 22, 2004
Amendment under 37 CFR 1.116 Expedited Procedure

PATENT

Amendments to the Claims:

This listing of claims will replace all prior listings of claims in the application:

Listing of Claims:

1.-52. (cancelled)

1 ~~53.~~ (previously presented) A monoclonal antibody which specifically binds to the epitope bound by a monoclonal antibody produced by any one of the hybridomas designated HB-12612, HB-12613, HB-12614, HB-12616, HB-12618, HB-12615, or HB-12617, as deposited with the American Type Culture Collection.

54.-55. (cancelled)

2 ~~56.~~ (previously presented) The monoclonal antibody of claim ~~53~~¹ which is a chimeric antibody.

3 ~~57.~~ (previously presented) The monoclonal antibody of claim ~~56~~², wherein the chimeric antibody is a humanized antibody.

4 ~~58.~~ (previously presented) A cell that produces the monoclonal antibody of claim ~~55~~¹.

5 ~~59.~~ (previously presented) A recombinant protein comprising the antigen binding region of the monoclonal antibody of claim ~~53~~¹.

6 ~~60.~~ (previously presented) An Fab, F(ab')₂ or Fv fragment of the monoclonal antibody of claim ~~53~~¹.

7 ~~61.~~ (previously presented) An immunoconjugate comprising a cytotoxic agent and the monoclonal antibody of claim ~~53~~¹.

Best Available Copy

Appl. No. 09/934,773
Amdt. dated April 22, 2004
Amendment under 37 CFR 1.116 Expedited Procedure

PATENT

~~8/82.~~ (previously presented) An immunoconjugate comprising a cytotoxic agent and the recombinant protein of claim ~~59.5~~

~~63.-86.~~ (cancelled)

~~9/87.~~ (previously presented) A composition, comprising an amount of the antibody of claim 53 that specifically binds to SEQ ID NO.: 2, and a pharmaceutically acceptable carrier.

~~1/88.~~ (previously presented) A kit comprising the monoclonal antibody of claim ~~53~~ and a detectable label.

~~1/89.~~ (previously presented) A monoclonal antibody of claim ~~53~~ which specifically binds to the epitope bound by the monoclonal antibody designated 1G8, 2A2, 2H9, 3C5, 3E6, 3G3 or 4A10, such that the antibody competitively inhibits the immunospecific binding of any of the monoclonal antibodies designated 1G8, 2A2, 2H9, 3C5, 3E6, 3G3 or 4A10, respectively, to PSCA of SEQ ID NO: 2.

~~1/90.~~ (previously presented) A monoclonal antibody of claim ~~89~~ which specifically binds to the epitope bound by the monoclonal antibody designated 1G8, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 1G8 to PSCA of SEQ ID NO: 2.

~~1/3/91.~~ (previously presented) A monoclonal antibody of claim ~~89~~ which specifically binds to the epitope bound by the monoclonal antibody designated 2A2, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 2A2 to PSCA of SEQ ID NO: 2.

~~1/4/92.~~ (previously presented) A monoclonal antibody of claim ~~89~~ which specifically binds to the epitope bound by the monoclonal antibody designated 2H9, wherein the

Best Available Copy

Appl. No. 09/934,773
Amdt. dated April 22, 2004
Amendment under 37 CFR 1.116 Expedited Procedure

PATENT

antibody competitively inhibits the immunospecific binding of the monoclonal antibody 2H9 to PSCA of SEQ ID NO: 2.

~~15~~ ¹¹ ~~93~~. (previously presented) A monoclonal antibody of claim ~~89~~ which specifically binds to the epitope bound by the monoclonal antibody designated 3C5, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 3C5 to PSCA of SEQ ID NO: 2.

~~16~~ ¹¹ ~~94~~. (previously presented) A monoclonal antibody of claim ~~89~~ which specifically binds to the epitope bound by the monoclonal antibody designated 3E6, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 3E6 to PSCA of SEQ ID NO: 2.

~~17~~ ¹¹ ~~95~~. (previously presented) A monoclonal antibody of claim ~~89~~ which specifically binds to the epitope bound by the monoclonal antibody designated 3G3, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 3G3 to PSCA of SEQ ID NO: 2.

~~18~~ ¹¹ ~~96~~. (previously presented) A monoclonal antibody of claim ~~89~~ which specifically binds to the epitope bound by the monoclonal antibody designated 4A10, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 4A10 to PSCA of SEQ ID NO: 2.

~~19~~ ¹¹ ~~97~~. (previously presented) A monoclonal antibody of claim ~~89~~ which specifically binds to the epitope bound by a monoclonal antibody produced by any one of the hybridomas designated HB-12612, HB-12613, HB-12614, HB-12616, HB-12615, HB-12618, or HB-12617, as deposited with the American Type Culture Collection.

~~20~~ ¹¹ ~~98~~. (previously presented) A monoclonal antibody which immunospecifically binds the epitope bound by the monoclonal antibody designated 2A2 or 3G3, produced by the

Best Available Copy

Appl. No. 09/934,773
Amdt. dated April 22, 2004
Amendment under 37 CFR 1.116 Expedited Procedure

PATENT

hybridomas designated HB-12613, or HB-12615, respectively, as deposited with the American Type Culture Collection.

99. cancelled

21 100. (new) The monoclonal antibody of claim 90, wherein the antibody is a chimeric antibody.

22 101. (new) The monoclonal antibody of claim 100, wherein the chimeric antibody is a humanized antibody.

23 102 (new) The monoclonal antibody of claim 90, wherein the antibody is a human antibody.

Best Available Copy